All In Biotech

Drug Trial Radar · NCT07774403

A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

A Phase II Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jun 24, 2026

Primary completion

Jan 18, 2028

Study completion Jun 6, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Conditions

  • Bronchiectasis With Pseudomonas Aeruginosa Colonization

Interventions

  • AZD0292Drug

    AZD0292 administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.

  • PlaceboOther

    Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of exacerbations over a variable follow-up timeTime frame: Min 28 weeks, max 52 weeks

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Anyang, China · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Changsha, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chizhou, China · Recruiting

  • Research Site

    Haikou, China · Recruiting

  • Research Site

    Hefei, China · Recruiting

  • Research Site

    Hohhot, China · Recruiting

  • Research Site

    Hohhot, China · Recruiting

  • Research Site

    Jinan, China · Recruiting

  • Research Site

    Jinhua, China · Recruiting

  • Research Site

    Jining, China · Recruiting

  • Research Site

    Kunming, China · Recruiting

  • Research Site

    Langfang, China · Recruiting

  • Research Site

    Linhai, China · Recruiting

  • Research Site

    Liuzhou, China · Recruiting

  • Research Site

    Nanchang, China · Recruiting

  • Research Site

    Nanchang, China · Recruiting

  • Research Site

    Nanning, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shenyang, China · Recruiting

  • Research Site

    Taicang, China · Recruiting

  • Research Site

    Taizhou, China · Recruiting

  • Research Site

    Wenzhou, China · Recruiting

  • Research Site

    Xinxiang, China · Recruiting

  • Research Site

    Xuzhou, China · Recruiting

  • Research Site

    Zaozhuang, China · Recruiting

  • Research Site

    Zhangzhou, China · Recruiting

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Zhuzhou, China · Recruiting

  • Research Site

    Zibo, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.